The rationale behind grafting haploidentical hematopoietic stem cells
The ability to perform hematopoietic cell transplant across major histocompatibility complex barriers can dramatically increase the availability of donors and allow more patients across the world to pursue curative transplant procedures for underlying hematologic disorders. Early attempts at haploid...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Hematology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/16078454.2024.2347673 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850061192058372096 |
|---|---|
| author | Richard T. Maziarz Rachel J. Cook |
| author_facet | Richard T. Maziarz Rachel J. Cook |
| author_sort | Richard T. Maziarz |
| collection | DOAJ |
| description | The ability to perform hematopoietic cell transplant across major histocompatibility complex barriers can dramatically increase the availability of donors and allow more patients across the world to pursue curative transplant procedures for underlying hematologic disorders. Early attempts at haploidentical transplantation using broadly reactive T-cell depletion approaches were compromised by graft rejection, graft-versus-host disease and prolonged immune deficiency. The evolution of haploidentical transplantation focused on expanding transplanted hematopoietic progenitors as well as using less broadly reactive T-cell depletion. Significant outcome improvements were identified with technology advances allowing selective depletion of donor allospecific T cells, initially ex-vivo with evolution to its current in-vivo approach with the infusion of the highly immunosuppressive chemotherapy agent, cyclophosphamide after transplantation procedure. Current approaches are facile and portable, allowing expansion of allogeneic hematopoietic cell transplantation for patients across the world, including previously underserved populations. |
| format | Article |
| id | doaj-art-d4e737183a0145b4862819f0362616cf |
| institution | DOAJ |
| issn | 1607-8454 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Hematology |
| spelling | doaj-art-d4e737183a0145b4862819f0362616cf2025-08-20T02:50:19ZengTaylor & Francis GroupHematology1607-84542024-12-0129110.1080/16078454.2024.2347673The rationale behind grafting haploidentical hematopoietic stem cellsRichard T. Maziarz0Rachel J. Cook1Center for Hematologic Malignancies, Division of Hematology & Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USACenter for Hematologic Malignancies, Division of Hematology & Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USAThe ability to perform hematopoietic cell transplant across major histocompatibility complex barriers can dramatically increase the availability of donors and allow more patients across the world to pursue curative transplant procedures for underlying hematologic disorders. Early attempts at haploidentical transplantation using broadly reactive T-cell depletion approaches were compromised by graft rejection, graft-versus-host disease and prolonged immune deficiency. The evolution of haploidentical transplantation focused on expanding transplanted hematopoietic progenitors as well as using less broadly reactive T-cell depletion. Significant outcome improvements were identified with technology advances allowing selective depletion of donor allospecific T cells, initially ex-vivo with evolution to its current in-vivo approach with the infusion of the highly immunosuppressive chemotherapy agent, cyclophosphamide after transplantation procedure. Current approaches are facile and portable, allowing expansion of allogeneic hematopoietic cell transplantation for patients across the world, including previously underserved populations.https://www.tandfonline.com/doi/10.1080/16078454.2024.2347673Haploidentical transplantationHLA mismatchgraft vs host diseasegraft rejection |
| spellingShingle | Richard T. Maziarz Rachel J. Cook The rationale behind grafting haploidentical hematopoietic stem cells Hematology Haploidentical transplantation HLA mismatch graft vs host disease graft rejection |
| title | The rationale behind grafting haploidentical hematopoietic stem cells |
| title_full | The rationale behind grafting haploidentical hematopoietic stem cells |
| title_fullStr | The rationale behind grafting haploidentical hematopoietic stem cells |
| title_full_unstemmed | The rationale behind grafting haploidentical hematopoietic stem cells |
| title_short | The rationale behind grafting haploidentical hematopoietic stem cells |
| title_sort | rationale behind grafting haploidentical hematopoietic stem cells |
| topic | Haploidentical transplantation HLA mismatch graft vs host disease graft rejection |
| url | https://www.tandfonline.com/doi/10.1080/16078454.2024.2347673 |
| work_keys_str_mv | AT richardtmaziarz therationalebehindgraftinghaploidenticalhematopoieticstemcells AT racheljcook therationalebehindgraftinghaploidenticalhematopoieticstemcells AT richardtmaziarz rationalebehindgraftinghaploidenticalhematopoieticstemcells AT racheljcook rationalebehindgraftinghaploidenticalhematopoieticstemcells |